John Houston, Arvinas CEO
Arvinas’ prostate cancer treatment shows hints of signal — but how many patients will it work for?
Arvinas released interim results Thursday morning on one of its protein degrader drugs for prostate cancer ahead of a fireside chat …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
